Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions-Reference-Cited by-同舟云学术

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions

Published:2017-07-31 Issue: Volume:8 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Beirnaert Els,Desmyter Aline,Spinelli Silvia,Lauwereys Marc,Aarden Lucien,Dreier Torsten,Loris Remy,Silence Karen,Pollet Caroline,Cambillau Christian,de Haard Hans

Funder

Ablynx

Centre National de la Recherche Scientifique

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference42 articles.

1. Dendritic cells and cytokines in human inflammatory and autoimmune diseases;Blanco;Cytokine Growth Factor Rev,2008

2. Tumor necrosis factor signaling;Wajant;Cell Death Differ,2003

3. TNF receptor 2 pathway: drug target for autoimmune diseases;Faustman;Nat Rev Drug Discov,2010

4. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1;Steeland;J Biol Chem,2015

5. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation;Banner;Cell,1993

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy;Biochemical and Biophysical Research Communications;2024-11

2. Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis;RMD Open;2024-08

3. The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors;2024-07-30

4. Synthetic Amine Linkers for Efficient Sortagging;Bioconjugate Chemistry;2024-07-12

5. Single-domain antibodies as therapeutics for solid tumor treatment;Acta Pharmaceutica Sinica B;2024-07